Magnus Åstrand

Aug 25, 2024 | bpspubs.onlinelibrary.wiley.com | Muhammad Sadiq |Hongtao Yu |Magnus Åstrand |Ian Scott

What is already known about this subject Tozorakimab, a high-affinity human monoclonal antibody, neutralizes IL-33. In a phase 1 study in healthy adults and patients with chronic obstructive pulmonary disease, tozorakimab was well tolerated and demonstrated linear and time-independent pharmacokinetics (PK). Biomarker measurements of the IL-33/tozorakimab and IL-33/sST2 complexes demonstrated target engagement (TE) in systemic circulation.